glp-1 and type 2 diabetes GLP-1RAs Reduce External Eating Behavior with Eating Behaviors May Predict GLP-1

Reduction in Risk Across Fourteen Obesity-Related Cancers A large observational study presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2025, involving more than 170,000 patients with diabetes and obesity, found that GLP-1 receptor agonists were associated with a modest but statistically meaningful reduction in the incidence of 14 obesity-related cancers , with colorectal cancer demonstrating particularly favourable outcomes when compared to patients receiving DPP-4 inhibitors

doi: 10.1001/archpediatrics.2012.49 10 VajraveluMETasEArslanianS

Ilenia D'Ippolito, Myriam Angelica Carlucci, Cinzia D'Amato, Davide Lauro, Vincenza Spallone Endocrine Practice.2024

UnitedHealthcare offers optional coverage for GLP-1 medications, primarily targeting clients or businesses that choose to include weight loss products in their plans